It would appear that Biogen (and their Japanese partner, Eisai) have struck out with getting aducanumab approved in the United States. But they have other options, and they are pursuing at least one. In this press release, they announced that the European Medicines Agency has agreed to review aducanumab for approved use in Europe. You can read more here.
But don't hold your breath. They got a pretty quick answer from the FDA panel's recommendation (or slapdown), but the European process will take 210 days. We'll see what that yields.
No comments:
Post a Comment